← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2002First marketed drug
Oct 4, 1993First NDA
Sep 30, 1997Last known activity
Aug 1, 2012
Acquired by Teva on Oct 14, 2011
Timeline
1980s
- Jan 1, 1987
Cephalon— Founded
1990s
- Oct 4, 1993
fentanyl— NDA Secondary Org
2000s
- Oct 12, 2000
Anesta— Acquired
- Jun 17, 2005
Salmedix— Acquired
- Dec 6, 2005
Zeneus Pharma— Acquired
- Jun 15, 2007
armodafinil— NDA Organization
- Feb 27, 2009
Arana Therapeutics Ltd— Acquired
2010s
- Feb 1, 2010
Mepha Ltd.— Acquired
- Apr 6, 2010
Ception— Acquired
- Feb 17, 2011
Alba Therapeutics— Acquired
- Mar 29, 2011
ChemGenex Pharmaceuticals— Acquired
- Jun 16, 2011
Gemin X— Acquired
- Oct 14, 2011
Teva— Acquired By
Drugs by trial phase (68 distinct, 191 trials)
Phase 4 (7 own, 6 via acquisition)
Phase 3 (8 own, 9 via acquisition)
Phase 2 (17 own, 9 via acquisition)
Phase 1 (10 own, 2 via acquisition)
Indications
Approved for
Studied for
- Alcohol Drinking
- Alcoholism
- Alzheimer Disease
- Amyloidosis
- Amyotrophic Lateral Sclerosis
- Anemia, Sickle Cell
- Anxiety Disorders
- Apnea
- Asthma
- Attention Deficit Disorder with Hyperactivity
- Back Pain
- Binge-Eating Disorder
- Bipolar Disorder
- Brain Injuries
- Brain Injuries, Traumatic
- Brain Neoplasms
- Breakthrough Pain
- Breast Neoplasms
- Bulimia
- Cancer Pain
- Carcinoma, Ovarian Epithelial
- Carcinoma, Small Cell
- Central Nervous System Neoplasms
- Chronic Pain
- Cognition Disorders
- Cognitive Dysfunction
- Dementia
- Depression
- Depressive Disorder
- Diabetic Neuropathies
- Disease
- Disorders of Excessive Somnolence
- Dysthymic Disorder
- Endometrial Neoplasms
- Eosinophilic Esophagitis
- Esophagitis
- Fatigue
- Feeding and Eating Disorders
- Fibromyalgia
- Glioma
- Hodgkin Disease
- Hyperkinesis
- Immunoglobulin Light-chain Amyloidosis
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Promyelocytic, Acute
- Lewy Body Disease
- Liver Diseases
- Low Back Pain
- Lung Neoplasms
- Lupus Erythematosus, Systemic
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Major Depressive Disorder
- Mental Disorders
- Migraine Disorders
- Motor Neuron Disease
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myofascial Pain Syndromes
- Narcolepsy
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Nervous System Neoplasms
- Neuralgia
- Osteoarthritis
- Osteoporosis
- Ovarian Neoplasms
- Overweight
- Parasomnias
- Parkinson Disease
- Phobia, Social
- Polycythemia
- Polycythemia Vera
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Primary Myelofibrosis
- Prostatic Neoplasms
- Psoriasis
- Psychotic Disorders
- Pulmonary Eosinophilia
- Renal Insufficiency
- Sarcoidosis
- Schizophrenia
- Sciatica
- Sclerosis
- Sleep Apnea, Obstructive
- Sleep Apnea Syndromes
- Sleep Deprivation
- Sleep Disorders, Circadian Rhythm
Marketed drugs (6)
Subsidiaries (9 direct, 9 total across the full acquisition tree)
Recent trials (50)
- NCT01563601Lead sponsorPhase 3Aug 1, 2012
- NCT01626352CollaboratorPhase 2Aug 1, 2012
- NCT01222260CollaboratorPhase 2Jun 1, 2012
- NCT01596673Lead sponsorPhase 1Mar 1, 2012
- NCT01596673Study directorPhase 1Mar 1, 2012
- NCT01315873CollaboratorPhase 2Sep 1, 2011
- NCT01348919Study directorPhase 1/Phase 2Aug 1, 2011
- NCT01348919Lead sponsorPhase 1/Phase 2Aug 1, 2011
- NCT01470248CollaboratorPhase 2Aug 1, 2011
- NCT01272245CollaboratorPhase 2Jul 1, 2011
- NCT01367028CollaboratorPhase 2Jun 1, 2011
- NCT01290887Study directorPhase 3Jun 1, 2011
- NCT01345357Lead sponsorPhase 1May 1, 2011
- NCT01345357Study directorPhase 1May 1, 2011
- NCT01169753CollaboratorN/AMay 1, 2011
Details
- Founded
- Malvern, PA, US Jan 1, 1987
- First NDA
- Sep 30, 1997
- Last known activity
- Aug 1, 2012
Designations held
- Orphan drug
- Priority review
Notes
Acquired by Teva